Related scientific articles (all)

CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines.

Authors : Fumagalli D, Michiels S, Sotiriou C
Year : 2011
Journal : Pharmacogenomics
Volume : 12(1)
Pages : 12-3

Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis.

Authors : Filho OM, Ignatiadis M, Sotiriou C
Year : 2011
Journal : Crit Rev Oncol Hematol
Volume : 77(1)
Pages : 20-9

ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.

Authors : Sircoulomb F, Nicolas N, Ferrari A, Finetti P, Bekhouche I, Rousselet E, Lonigro A, Adélaïde J, Baudelet E, Esteyriès S, Wicinski J, Audebert S, Charafe-Jauffret E, Jacquemier J, Lopez M, Borg JP, Sotiriou C, Popovici C, Bertucci F, Birnbaum D, Chaffanet M, Ginestier C
Year : 2011
Journal : EMBO Mol Med
Volume : 3(3)
Pages : 153-66

Genes expressed in specific areas of the human fetal cerebral cortex display distinct patterns of evolution.

Authors : Lambert N, Lambot MA, Bilheu A, Albert V, Englert Y, Libert F, Noel JC, Sotiriou C, Holloway AK, Pollard KS, Detours V, Vanderhaeghen P
Year : 2011
Journal : PLoS One
Volume : 6(3)
Pages : e17753

Evaluation of the Infinium Methylation 450K technology.

Authors : Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F
Year : 2011
Journal : Epigenomics
Volume : 3(6)
Pages : 771-84

Breast cancer: Should we assess HER2 status by Oncotype DX?

Authors : Ignatiadis M, Sotiriou C
Year : 2011
Journal : Nat Rev Clin Oncol
Volume : 9(1)
Pages : 12-4

Peptides targeting estrogen receptor alpha-potential applications for breast cancer treatment.

Authors : Leclercq G, Gallo D, Cossy J, Laïos I, Larsimont D, Laurent G, Jacquot Y
Year : 2011
Journal : Curr. Pharm. Des.
Volume : 17(25)
Pages : 2632-53

HER2-positive circulating tumor cells in breast cancer.

Authors : Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart-Gebhart M, Sotiriou C
Year : 2011
Journal : PLoS One
Volume : 6(1)
Pages : e15624

Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).

Authors : Altintas S, Toussaint J, Durbecq V, Lambein K, Huizing MT, Larsimont D, Van Marck E, Vermorken JB, Tjalma WA, Sotiriou C
Year : 2011
Journal : Breast J
Volume : 17(4)
Pages : 343-51

Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer.

Authors : Rothé F, Ignatiadis M, Chaboteaux C, Haibe-Kains B, Kheddoumi N, Majjaj S, Badran B, Fayyad-Kazan H, Desmedt C, Harris AL, Piccart-Gebhart M
Year : 2011
Journal : PLoS One
Volume : 6(6)
Pages : e20980

Gene profiling assay and application: the predictive role in primary therapy.

Authors : Fumagalli D, Desmedt C, Ignatiadis M, Loi S, Piccart-Gebhart M, Sotiriou C
Year : 2011
Journal : J. Natl. Cancer Inst. Monographs
Volume : 2011(43)
Pages : 124-7

Largest ever DNA methylation dataset for breast cancer completed.

Authors : Dedeurwaerder S, Desmedt C, Calonne E
Year : 2011
Journal : Expert Rev. Mol. Diagn.
Volume : 11(5)
Pages : 470

Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.

Authors : Li Q, Eklund AC, Birkbak NJ, Desmedt C, Haibe-Kains B, Sotiriou C, Symmans WF, Pusztai L, Brunak S, Richardson AL, Szallasi Z
Year : 2011
Journal : BMC Bioinformatics
Volume : 12(null)
Pages : 310

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Authors : Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H
Year : 2011
Journal : Lancet Oncol
Volume : 12(12)
Pages : 1134-42